Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03214757
Recruitment Status : Not yet recruiting
First Posted : July 12, 2017
Last Update Posted : January 10, 2018
Sponsor:
Information provided by (Responsible Party):
Mohamed Ahmed Amar, Assiut University

Brief Summary:

Dilated cardiomyopathy is a heart muscle disorder characterized by systolic dysfunction and dilation of the left or both ventricles.Dilated cardiomyopathy can develop in people of any age or ethnicity, although it is more common in male than female persons occurring at a ratio of about three to one in male to female persons.

Dilated cardiomyopathy is the predominant cause of cardiomyopathy in pediatric populations. Annual incidence in pediatric populations has been reported to be much lower than one to one hundred seventy thousand in the United States and one to one hundred forty thousand in Australia.

Although pediatric dilated cardiomyopathy has a lower annual incidence than adult dilated cardiomyopathy, the outcome for pediatric dilated cardiomyopathy patients is particularly severe.

Dilated cardiomyopathy is the most frequent cause of heart transplantation in pediatric patients. Data from international pediatric dilated cardiomyopathy registries indicate that the rates of death or heart transplantation over one and five year periods were thirty one percent and forty six percent, respectively.

Onset of dilated cardiomyopathy is usually insidious but may be acute in as many at twenty five percent of patients. Approximately fifty percent of patients with dilated cardiomyopathy have a history of preceding viral illness.


Condition or disease Intervention/treatment
Pediatric Dilated Cardiomyopathy Other: treatment of anemia.

Detailed Description:

The clinical diagnosis of dilated cardiomyopathy is made from history, physical examination, and noninvasive testing. The initial clinical manifestations of dilated heart failure are generally those of respiratory distress secondary to congestion of the pulmonary and systemic venous circulations.

Pallor, irritability, diaphoresis, tachypnea, easy fatigability are characteristics.

Failure to grow may also occur. In older patients, a history of orthopnea, nocturnal cough, and dyspnea provoked by minimal activity can be elicited and generally precede evidence of systemic venous congestion. In rapidly progressive disease, dominant symptoms are often abdominal distention, right upper quadrant pain, and nausea. Less often, initial symptoms in childhood include arrhythmias, syncope, neurologic problems (seizures or delayed development), vomiting, abdominal distention, or fever.

Although as many as fifty percent of children with cardiomyopathy and heart failure give a history of a nonspecific febrile illness within three months of presentation, no evidence of myocarditis can usually be found on biopsy.'Physical signs vary with the stage of the disease.

Signs of congestive heart failure are frequent, and include tachypnea,tachycardia, diaphoresis, hepatomegaly, pallor, and, in advanced cases, hypotension and shock.

Failure to thrive may be present if, heart failure has been long standing. Patients are generally not cyanotic. Wheezing may be heard; however, rales are infrequent, especially in infants.

Neck vein distension is common, the external jugular crest reflecting mean right atrial pressure, the internal jugular exhibiting a prominent V wave indicative of tricuspid regurgitation.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy
Estimated Study Start Date : February 2018
Estimated Primary Completion Date : August 2018
Estimated Study Completion Date : December 2018


Group/Cohort Intervention/treatment
group with dilated cardiomyopathy without anemia
group with dilated cardiomyopathy with anemia Other: treatment of anemia.
drug treatment of anemia.




Primary Outcome Measures :
  1. Heart failure [ Time Frame: four months duration after start of the study ]
    Through clinical manifestations of heart of heart failure and echocardiographic assesment of ventricular function


Other Outcome Measures:
  1. Quality of Well-Being Scale [ Time Frame: three months duration after start of the study ]
    To measure health related quality of life, to monitor the health of populations over time, or to evaluate the efficacy and effectiveness of clinical therapies of practices using a preference weighted self administered measure.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Months to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
All infants and children with dilated cardiomyopathy who are diagnosed clinically and by echocardiography attending cardiology outpatient clinic at Assiut University Children Hospital.
Criteria

Inclusion Criteria:

  • All infants and children with dilated cardiomyopathy who are diagnosed clinically and by echocardiography attending cardiology outpatient clinic at Assiut University Children Hospital will be included.

Exclusion Criteria:

  • Infants age less than two months.
  • Infants with hemolytic anemias.
  • Patients with congestive heart failure due to congenital heart disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03214757


Contacts
Layout table for location contacts
Contact: Nagwa Ali Mohammed, MD 0201096260950 Namma65@yahoo.com
Contact: Osama Mahmoud El-Asheer, MD 0201001348864 Asheer1970@gmail.com

Sponsors and Collaborators
Assiut University

Layout table for additonal information
Responsible Party: Mohamed Ahmed Amar, principal investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03214757     History of Changes
Other Study ID Numbers: NA_0000XXX
First Posted: July 12, 2017    Key Record Dates
Last Update Posted: January 10, 2018
Last Verified: January 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiomyopathies
Cardiomyopathy, Dilated
Heart Diseases
Cardiovascular Diseases
Cardiomegaly